Alnylam Pharmaceuticals Inc - Asset Resilience Ratio
Alnylam Pharmaceuticals Inc (ALNY) has an Asset Resilience Ratio of 25.19% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Alnylam Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Alnylam Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ALNY total asset value.
Liquid Assets Composition Over Time
This chart breaks down Alnylam Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ALNY long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.25 Billion | 25.19% |
| Total Liquid Assets | $1.25 Billion | 25.19% |
Asset Resilience Insights
- Very High Liquidity: Alnylam Pharmaceuticals Inc maintains exceptional liquid asset reserves at 25.19% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Alnylam Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Alnylam Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Alnylam Pharmaceuticals Inc (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Alnylam Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 25.19% | $1.25 Billion | $4.97 Billion | -15.56pp |
| 2024-12-31 | 40.76% | $1.73 Billion | $4.24 Billion | -1.72pp |
| 2023-12-31 | 42.47% | $1.63 Billion | $3.83 Billion | +5.08pp |
| 2022-12-31 | 37.39% | $1.33 Billion | $3.55 Billion | -6.95pp |
| 2021-12-31 | 44.34% | $1.62 Billion | $3.64 Billion | +3.90pp |
| 2020-12-31 | 40.44% | $1.38 Billion | $3.41 Billion | -0.85pp |
| 2019-12-31 | 41.29% | $988.98 Million | $2.40 Billion | -0.87pp |
| 2018-12-31 | 42.16% | $664.01 Million | $1.57 Billion | -10.24pp |
| 2017-12-31 | 52.40% | $1.05 Billion | $1.99 Billion | +18.10pp |
| 2016-12-31 | 34.30% | $433.18 Million | $1.26 Billion | -30.58pp |
| 2015-12-31 | 64.88% | $899.64 Million | $1.39 Billion | +7.32pp |
| 2014-12-31 | 57.57% | $621.51 Million | $1.08 Billion | +11.75pp |
| 2013-12-31 | 45.82% | $192.70 Million | $420.53 Million | +20.99pp |
| 2012-12-31 | 24.84% | $71.41 Million | $287.52 Million | -2.18pp |
| 2011-12-31 | 27.02% | $76.17 Million | $281.92 Million | -13.29pp |
| 2010-12-31 | 40.31% | $158.53 Million | $393.26 Million | +10.41pp |
| 2009-12-31 | 29.90% | $143.93 Million | $481.38 Million | -13.12pp |
| 2008-12-31 | 43.02% | $238.60 Million | $554.68 Million | -14.66pp |
| 2007-12-31 | 57.67% | $284.79 Million | $493.79 Million | +20.46pp |
| 2006-12-31 | 37.21% | $89.31 Million | $240.01 Million | -28.11pp |
| 2005-12-31 | 65.32% | $64.25 Million | $98.35 Million | +26.34pp |
| 2004-12-31 | 38.99% | $25.77 Million | $66.11 Million | +37.93pp |
| 2003-12-31 | 1.06% | $373.00K | $35.18 Million | +0.94pp |
| 2002-12-31 | 0.12% | $19.00K | $16.11 Million | -- |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute h… Read more